US Patent Issued to Corcept Therapeutics on March 31 for "Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4" (British, American Inventors)

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,589,094, issued on March 31, was assigned to Corcept Therapeutics Inc. (Redwood City, Calif.).

"Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4" was invented by Hazel Hunt (Storrington, Great Britain) and Joseph Custodio (Menlo Park, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein.Relacorilant poten...